In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.

The firm's stock price dropped 27 percent on Tuesday following the news that the young man died from acute liver failure after getting Elevidys.

Precision Medicine Online's 2024 survey shows biomarker test expansion but low clinical trial enrollment and long wait times for advanced therapies.